Compare · CBUS vs EVGN
CBUS vs EVGN
Side-by-side comparison of Cibus Inc. (CBUS) and Evogene Ltd (EVGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBUS and EVGN operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- CBUS is the larger of the two at $128.4M, about 14.8x EVGN ($8.7M).
- EVGN has been more active in the news (8 items in the past 4 weeks vs 3 for CBUS).
- Both have 4 recent analyst ratings on file.
- Company
- Cibus Inc.
- Evogene Ltd
- Price
- -
- -
- Market cap
- $128.4M
- $8.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 3
- 8
- Recent ratings
- 4
- 4
Evogene Ltd
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Latest CBUS
- SEC Form 10-Q filed by Cibus Inc.
- Cibus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cibus Reports Second Quarter Financial Results and Provides Business Update
- Cibus to Report Second Quarter 2026 Financial Results on August 13, 2026 After the Market Close and Host Conference Call
- SEC Form S-8 filed by Cibus Inc.
- SEC Form S-8 filed by Cibus Inc.
- Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus
- CEO Wichner Craig was granted 894,309 shares (SEC Form 4)
- Cibus Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation
Latest EVGN
- Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees
- Evogene Reports Second Quarter and First Half 2026 Financial Results
- SEC Form 6-K filed by Evogene Ltd
- Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
- Amendment: SEC Form SCHEDULE 13D/A filed by Evogene Ltd
- Director Recanati Leon bought $292,100 worth of Ordinary Shares (460,000 units at $0.64), increasing direct ownership by 52% to 1,343,886 units (SEC Form 4)
- SEC Form SCHEDULE 13D filed by Evogene Ltd
- Director Recanati Leon bought $400,000 worth of Ordinary Shares (800,000 units at $0.50), increasing direct ownership by 954% to 883,886 units (SEC Form 4)
- SEC Form 6-K filed by Evogene Ltd
- Evogene Schedules Second Quarter 2026 Financial Results Release